Amylyx Pharmaceuticals, Inc.
AMLX
Kedudukan dalam Saham
#4491
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$27.25
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.42B
Perubahan (1 hari)
3.45%
Perubahan (1 tahun)
77.29%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Bilangan saham terbitan bagi Amylyx Pharmaceuticals, Inc. (AMLX)
Bilangan saham terbitan setakat June 2026: 111.20M
Menurut laporan kewangan terkini dan harga saham Amylyx Pharmaceuticals, Inc., bilangan saham terbitan semasa ialah 111.20M. Pada akhir December 2023, syarikat mempunyai 67.23M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Amylyx Pharmaceuticals, Inc. (AMLX) dari 2019 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 111.20M | 63.18% |
| 2024 | 68.14M | 1.35% |
| 2023 | 67.23M | 1.09% |
| 2022 | 66.51M | 14.95% |
| 2021 | 57.86M | 2.48% |
| 2020 | 56.47M | 0.00% |
| 2019 | 56.47M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 128.33% |
US
|
|
| 396.00M | 256.13% |
US
|
|
| 478.91M | 330.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -44.08% |
NL
|
